Comparison between Prolonged Administration of Oral Etoposide and UFT Combined with Intravenous Cisplatin-based Chemotherapy in Postoperative Non-small Cell Lung Cancer: a Randomized Trial by Tagawa Yutaka et al.
Acta Med. Nagasaki 44 : 24-28
Comparison between Prolonged Administration of Oral Etoposide and 
UFT Combined with Intravenous Cisplatin-based Chemotherapy in 
Postoperative Non-small Cell Lung Cancer: a Randomized Trial
Yutaka TAGAWA 1), Hiroyoshi AYABE 1), Masao TOMITA 1), Yasunori MATUZAKI 2), Koichiro SHIBATA 2), 
Koichi TANAKA 3), Yuzo UCHIDA 3), Mitsutoshi ICHIMANDA 4)
1) First Department of Surgery, Nagasaki University School of Medicine 
2) Second Department of Surgery, Miyazaki Medical University 
3) Second Department of Surgery, Oita Medical University 
4) Oita City Medical Association, Almeida Memorial Hospital
 Oral administration of etoposide or UFT is generally used 
in outpatient treatment of non-small cell lung cancer (NSCLC) 
after surgery in Japan. We examined the effectiveness of 
etoposide and UFT with relation to disease-free survival, over-
all survival and toxicity in postoperative NSCLC patients. In 
this study, a total of 50 patients were randomized to receive 
either, 25mg/day of etoposide, on a 2 week cycle (Group I-
25 cases) or 300mg/day of UFT, continuous administration 
(Group II-25 cases), after a Mitomycin C, Cisplatin and 
Vindesine, intravenous (i.v.). Disease-free and overall survival 
were better in Group II with 20 complete cases than in Group 
I with 15 complete cases. Furthermore, Group II achieved bet-
ter disease-free and overall survival rates than Group I with 
reference to stage IIIA and lymph node metastasis groups. 
There were no instances of severe toxicity in either group. 
Results of this study showed that prolonged oral admini-
stration of 25mg/day of etoposide is ineffective compared 
with oral UFT in NSCLC patients after surgical treatment. 
New randomized clinical trials of 50mg/day of etoposide 
will be necessary to determine usefulness and toxicity.
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Introduction
of NSCLC patients are increasing in Japan and Asia. 
Many institutes are carrying out clinical trials using new 
agents for advanced NSCLC. Chang et al." and Murphy 
et al." have reported that these agents have produced 
higher response rates in advanced NSCLC. However, tests 
of new agents are still being conducted to determine if 
toxicity will be a problem" At present, Cisplatin (CDDP)-
based chemotherapy is still one of the most commonly 
used postoperative chemotherapies for recurrence pre-
vention in NSCLC patients after surgical treatment. 
 Oral administration of anticancer drugs, if there is no 
severe toxicity problem, needs to be introduced in out-
patient treatments to contribute to the increase of the 
QOL of the patient after surgical resection. Presently, 
two drugs, etoposide and UFT are used as oral admini-
stration in postoperative chemotherapy. Although clini-
cal trials of UFT alone were performed in several in-
stitutes"-6', etoposide has been used in few trials follow-
ing scientific protocols. To the authors' knowledge there 
are no reports regarding comparisons between prolonged 
oral administration of UFT and etoposide after surgery, 
although there is a report of etoposide + UFT combined 
with Carboplatin in advanced NSCLC'.' 
 The purpose of this clinical trial have shown whether 
or not oral administration of either etoposide or UFT has 
an impact on prognosis in NSCLC patient populations 
after surgery.
 Chemotherapy has proven to be ineffective in treating 
non-small cell lung cancer (NSCLC), while the number
Patients and Methods
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 The medical records of 50 patients who underwent 
thoracotomy for the treatment of NSCLC at the four 
collaborative institutes in Kyushu area between May,
1991 and December, 1993 were reviewed to identify 
patients who had undergone a curative or a relative 
curative operation (p-stage I, II and IIIA) according to 
pathological findings. Patients were assigned a patho-
logical stage in accordance with the staging system of 
The General Rule of The Japan Lung Cancer Society 
(The 3rd Edition) 8'. 
 Eligibility criteria included : 1) Patients less than 75 
years old. 2) Patients with no prior therapy and a 
Performance status of 0, 1 or 2. 3) Hematological ex-
aminations with WBC<4000/mm3, PTL< 10000/mm3, 
Cr> 1.5mg, CCr<60m1/min and up to 2 times normal 
GOT and GPT. Patients with recent cardiac disease, in-
fection and double cancers were excluded. All patients 
and/or families gave informed consent. The study was 
a randomized trial by closed envelope method. 
 Treatment methods were administered as follows : 
Immediately, 12mg/m2 of Mitomycin C were adminis-
tered intravenously after completion of surgical resec-
tion. Next, 80mg/m2 of CDDP and 3mg/m2 of Vindesine 
were administered intravenously once from 2 to 4 weeks 
later. After a hematological examination, the patients 
were divided into two groups (Group I and II) by closed 
envelope method. From 2 to 3 weeks after administra-
tion of CDDP and Vindesine, Group I received an oral 
dose of 25mg/day of etoposide and etoposide was given 
daily on 2 week cycles. Group II received daily 300mg 
oral doses of UFT. During treatment, hematological 
checks and X-rays or CT examinations were performed 
at 2 to 4 week intervals (Fig. 1). Oral etoposide and 
UFT were discontinued if the leukocyte count fell below 
3000/mm3, the platelet count fell below 7000/mm3 or 
the liver or kidney showed signs of damage. It was 
also discontinued when a chief doctor diagnosed seri-
ous complications or patients disapproved of the trial. 
 The condition of Patients were evaluated regarding 
disease-free survival, overall survival and toxicity. Toxic-
MMC= mitomycin C, CDDP= cisplatin, VDS= vindesine, ETP= etoposide
Fig. 1 Regimen of treatment methods in Group I (etoposide) 
and Group II (UFT).
ity criteria were evaluated by the Japan Society of Clini-
cal Oncology of Vol. 21 in 1986. Patients who received 
oral doses of etoposide or UFT for more than 6 months 
were considered "complete cases", while those receiv-
ing treatment for less than 6 months were considered 
"incomplete cases"
. G-CSF did not be used in complete 
and incomplete cases of this study. 
 Differences between patient characteristics in the 2 
groups were evaluated using the x2 test. Disease-free 
and overall survival were calculated from the random-
ized data by the Kaplan-Meier method and the differ-
ences between the 2 groups were analyzed by a log-
rank test and generalized wilcoxon test. A p value of 
less than 0.05 denoted the presence of statistically sig-
nificant differences.
Results
 A total of 50 patients entered into this study. 15 out 
of 25 in Group I were complete cases, nine were incom-
plete cases consisting of 5 recurrences, 1 postoperative 
pneumonia, 1 disapproval and 2 myelosuppression, and 
an ineligible case was administrated other anticancer 
drug. 20 out of 25 in Group II were complete cases, 3 
were incomplete cases with recurrence, and 2 were in-
eligible cases who were administrated other anticancer 
drug. 
 There were no differences in clinicopathological fea-
tures of patient characteristics between Group I and II 
in complete cases (Table 1). In complete cases, the actual 
1-year disease-free survival rates of Group I and II were 
85.7% and 100%, respectively, while 3-year disease-
free survival rates for Group 1 and 2 were 63.5% and 
87.5%, respectively. Disease-free survival rates were bet-
ter in the Group II than in the Group I, though rates 
between the two groups were not statistically signifi-
cant (Fig. 2A). 1- and 3-year overall survival rates in 
Group I were 93.3% and 65.0%, respectively, while Group 
II rates were 100% and 94.1%, respectively. Again, there 
was no statistically significant difference in overall sur-
vival rates between the two groups (Fig. 2B). Addition-
ally, data were analyzed according to the classification 
of p-stage. In stage IIIA, disease-free and overall sur-
vival rates were better in the Group II than in the 
Group I, with a statistically significant difference be-
tween the two groups (Fig. 3). The relationship be-
tween survival and the condition of lymph nodes was 
also analyzed between two groups. There were no sta-
tistical significance for disease-free and overall sur-
vival rates in non-lymph node metastasis group, while 
in lymph node metastasis groups, disease-free and overall 
survival rates were significantly better in the Group II
Table 1. Characteristics in complete cases of Group I (etoposide) 
and Group II (UFT)
 Variables Group I (n=15) Group II (n=20) P-value 
Sex 
   male 9 15 NS * 
   female 6 5 
Age (year) 
   <65 9 14 
                                      NS 
    65 6 6 
Pathological stage 
                  8 10 
   II 2 3 NS 
   III A 5 7 
Performance status 
   0 16 17 
   1 0 1 NS 
   2 0 0 
Histological type 
    squamous 2 7 
   adeno. 13 10 NS 
   large 0 3 
The term of drug 
administration (day) 
                  296^-719 227-998 
   median (353) (359.5) NS
(A) Disease-Free Survival curve
* NS : Non stastically significance
(B) Overall Survival curve
Fig. 2 Disease-free and overall survival curves for complete 
cases in Group I (etoposide) and Group II (UFT).
Disease-Free Survival Overall survival
Fig. 3 Disease-free and overall survival curves for complete cases in each stage (stage I: (A), stage II: (B), stage IIIA: (C) ).
Disease-Free Survival Overall Survival
Fig. 4 Disease-free and overall survival curves for complete cases with non-lymph node metastasis group 
(A) and lymph node metastasis group (B).
than in the Group I (Fig. 4). There were no statistical 
significance for T-factor, histological type and grading 
between the two groups. Toxicity in 47 patients of in-
complete and complete cases is given in Table 2. One 
incomplete patient in Group I stopped administration 
of etoposide because of a Grade 3 gastrointestinal symp-
tom after 4 months. And, there were mild toxicities of 
Grade 1 and 2 in the great majority of patients in 
Groups I and II.
Discussion
 Prolonged administration of oral etoposide combined 
with CDDP is sometimes used to treat advanced NSCLC 
patients. Willer et al.9) reported that a 37% response 
rate was obtained with oral etoposide for the cycle of 21 
day administration after a CDDP i.v. in advanced NSCLC. 
Recently, Jeremic et al.") showed that prolonged admini-
stration of oral etoposide combined with a Carboplatin 
i.v. produced a significantly better prognosis than that 
of Carboplatin alone in advanced NSCLC. Additionally, 
one paper reported that oral administration of etoposide 
decreased tumor size in a recurrent patient after surgi-
cal treatment'.' Conversely, Hayasaka et al. 12) has pointed 
out that adjuvant postoperative chemotherapy with oral 
etoposide was not effective treatment for improvement
Table 2. Toxicity in all patients (n=47) in Group I (etoposide) 
and Group II (UFT)
                      Group I (n=24) Group II (n=23) 
Data abnormality 
 and Symptom Grade Total Grade Total 
                    0 1 2 3 4 Toxicity 0 1 2 3 4 Toxicity 
Haematologic 
 Leucocyte 11 3 8 2 54.2% 14 6 2 1 39.1% 
 Haemoglobine 18 3 3 25.0% 20 3 13.0% 
 Platelet 23 1 4.2% 22 1 4.3% 
Hepatic 
 GOT,GPT 23 1 4.2% 22 1 4.3% 
Renal 
 Creatinine 24 0.0% 22 1 4.3% 
 Creatinine Crearance 23 1 4.2% 23 0.0% 
 Al-p 24 0.0% 22 1 4.3% 
 hematuria 23 1 4.2% 23 0.0% 
 proteinurea 22 2 8.3% 23 0.0% 
Gastrointestinal 
 anorexia 8 4 11 1 66.7% 7 4 10 2 69.6% 
 nausea/vomiting 8 4 11 1 66.7% 5 2 13 3 78.3% 
 diarrhea 23 1 4.2% 22 1 4.3% 
Others 
 peripheral neuropathy 23 1 4.2% 23 0.0% 
 fever 23 1 4.2% 23 0.0% 
 alopecia 23 1 4.2% 21 2 8.7% 
 malaise 21 3 12.5% 20 3 13.0%
Toxicity grades were evaluated by the Japan Society of Clinical Oncology of Vol. 21 in 1986.
of disease-free and overall survival, though toxicity was 
not severe and long term oral administration was pos-
sible. 
 Concerning oral administration of UFT after surgical 
treatment, Tomita et al."' reported that groups treated 
with UFT alone or UFT combined with a Cisplatin and 
Vindesine i.v. obtained lower recurrence rates than a 
group which surgery was the only treatment. Particu-
larly, they recognized the usefulness of UFT alone after 
surgery. The UFT only group produced the best results 
among the three in their study. In this study, the authors 
compared etoposide and UFT, and whether prolonged 
oral administration was useful in outpatients after sur-
gical treatment. Results showed that oral administration 
of UFT gave a better prognosis than that of etoposide 
in complete patients group, though there was no sta-
tistical significance for disease-free and overall survival 
rates between the two groups. Furthermore, the authors 
examined the relationship among prognostic factors in 
detail. For stage IIIA patients, the anticancer effect of 
UFT was superior to etoposide. This study showed the 
same result as the reports of Tomita et al."' and Okimoto 
et al."'. Additionally, for lymph node condition of a 
strong prognostic factor, UFT showed better effective-
ness than etoposide for the lymph node metastasis 
groups. 
 However, there were several problems in this study. 
The first problem was dose concentration. It was pointed 
out that an oral dose of 25mg/day of etoposide was 
not effective for NSCLC patients, because it does not 
provide a high enough concentration in the blood for 
treatment of lung cancer. Therefore, a etoposide dose of 
50mg/day is needed to obtain any anticancer effect"". 
However, in earlier clinical experiments, the authors 
couldn't use the dose of 50mg/day because of the side 
effects of myelosuppression and gastrointestinal dam-
ages same as Uchida et al."). The second problem is the 
difference in administration methods. Difference between 
continuous (UFT) and 2 week cycle (etoposide) admini-
stration is a problem. The third problem was too many 
incomplete patients in the etoposide group, 5 patients 
had local and distant metastasis in early phase after 
surgical resection. 
 In a realistic situation, authors compared oral etoposide 
and UFT in the dose limitations of general clinical treat-
ment. The results of this study suggest that adjuvant 
chemotherapy of oral etoposide should not be use in 
NSCLC patients after surgical treatment although new 
clinical trials of 50mg / day will be necessarily. The 
authors believe that oral UFT may be a safe and effec-
tive anticancer drug for outpatients after surgical treat-
ment of NSCLC.
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